Sonoma Pharmaceuticals (SNOA)
(Delayed Data from NSDQ)
$3.02 USD
+0.01 (0.33%)
Updated Aug 6, 2025 03:59 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SNOA 3.02 +0.01(0.33%)
Will SNOA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SNOA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNOA
Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum
Fast-paced Momentum Stock Sonoma Pharmaceuticals (SNOA) Is Still Trading at a Bargain
SNOA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Fast-paced Mover Sonoma Pharmaceuticals (SNOA) Is a Great Choice for Value Investors
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock
Beat the Market Like Zacks: Starbucks, Shopify, 3M in Focus
Other News for SNOA
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | SNOA ...
Sonoma Pharmaceuticals GAAP EPS of -$0.48, revenue of $3.75M